^
    Back
    Association details:
    Biomarker:EGFR mutation + EGFR T790M + EGFR C797S
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

    Published date:
    03/13/2020
    Excerpt:
    Interestingly enough, patients showing this “triplet pattern” (sensitizing+/T790M+/C797S+) tended to exhibit longer PFS and OS than patients who did not (P=0.1, Figure S1)….At this time, the p.C797S mutation was found along with the p.T790M mutation as well as the original EGFR-sensitizing mutation in 3...
    DOI:
    10.21037/tlcr.2020.04.01